medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 2

<< Back Next >>

Rev Mex Urol 2022; 82 (2)

Clinical variables in the diagnosis and treatment of advanced hormone sensitive prostate cancer

Zonana-Farca E, Ramírez-Pérez EA

Language: Spanish
References: 34
Page:
PDF size: 134.39 Kb.


ABSTRACT

In the last years, novel imaging studies have surged for increase the sensitivity in early metastatic disease detection. the recognition of biological subgroups of men with newly diagnosed advanced prostate cancer for the management of the primary tumor to improve the overall survival in this patients considered fatal in the short or medium term with systemic disease managed just with androgenic hormonal suppression.


REFERENCES

  1. Buyyounouski MK, Choyke PL, McKenneyJK, Sartor O, Sandler HM, Amin MB, etal. Prostate cancer - major changes in theAmerican Joint Committee on Cancer eighthedition cancer staging manual. CA Cancer JClin. 2017;67(3):245–53. doi: https://doi.org/10.3322/caac.21391

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics,2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.doi: https://doi.org/10.3322/caac.21551.

  3. Briganti A, Suardi N, Capogrosso P, Passoni N,Freschi M, di Trapani E, et al. Lymphatic spreadof nodal metastases in high-risk prostate cancer:The ascending pathway from the pelvis to theretroperitoneum. The Prostate. 2012;72(2):186–92. doi: https://doi.org/10.1002/pros.21420

  4. Hellman S, Weichselbaum RR. Oligometastases.J Clin Oncol. 1995;13(1):8–10. doi: https://ascopubs.org/doi/10.1200/JCO.1995.13.1.8

  5. Parker CC, James ND, Brawley CD, ClarkeNW, Hoyle AP, Ali A, et al. Radiotherapyto the primary tumour for newly diagnosed,metastatic prostate cancer (STAMPEDE): arandomised controlled phase 3 trial. The Lancet.2018;392(10162):2353–66. doi: https://doi.org/10.1016/S0140-6736(18)32486-3

  6. Boevé LMS, Hulshof MCCM, Vis AN,Zwinderman AH, Twisk JWR, WitjesWPJ, et al. Effect on Survival of AndrogenDeprivation Therapy Alone Compared toAndrogen Deprivation Therapy Combined withConcurrent Radiation Therapy to the Prostatein Patients with Primary Bone MetastaticProstate Cancer in a Prospective RandomisedClinical Trial: Data from the HORRAD Trial.Eur Urol. 2019;75(3):410–8. doi: https://doi.org/10.1016/j.eururo.2018.09.008

  7. Kyriakopoulos CE, Chen Y-H, CarducciMA, Liu G, Jarrard DF, Hahn NM, et al.Chemohormonal Therapy in MetastaticHormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the RandomizedPhase III E3805 CHAARTED Trial. J Clin Oncol.2018;36(11):1080–7. doi: https://ascopubs.org/doi/10.1200/JCO.2017.75.3657

  8. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abirateroneplus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journalof Medicine. 2017 Jul 27;377(4):352–60. doi:https://doi.org/10.1056/NEJMoa1704174

  9. Gillessen S, Attard G, Beer TM, BeltranH, Bjartell A, Bossi A, et al. Managementof Patients with Advanced Prostate Cancer:Report of the Advanced Prostate CancerConsensus Conference 2019. Eur Urol.2020 Apr;77(4):508–47. doi: https://doi.org/10.1016/j.eururo.2020.01.012

  10. Briganti A, Abdollah F, Nini A, Suardi N, GallinaA, Capitanio U, et al. Performance Characteristicsof Computed Tomography in Detecting LymphNode Metastases in Contemporary Patientswith Prostate Cancer Treated with ExtendedPelvic Lymph Node Dissection. EuropeanUrology. 2012;61(6):1132–8. doi: https://doi.org/10.1016/j.eururo.2011.11.008

  11. Gabriele D, Collura D, Oderda M, SturaI, Fiorito C, Porpiglia F, et al. Is there stilla role for computed tomography and bonescintigraphy in prostate cancer staging? Ananalysis from the EUREKA-1 database. WorldJ Urol. 2016;34(4):517–23. doi: https://link.springer.com/article/10.1007/s00345-015-1669-2

  12. van Leeuwen PJ, Emmett L, Ho B, Delprado W,Ting F, Nguyen Q, et al. Prospective evaluationof 68Gallium-prostate-specific membraneantigen positron emission tomography/computed tomography for preoperativelymph node staging in prostate cancer. BJUInt. 2017;119(2):209–15. doi: https://doi.org/10.1111/bju.13540

  13. Perera M, Papa N, Roberts M, WilliamsM, Udovicich C, Vela I, et al. Gallium-68Prostate-specific Membrane Antigen PositronEmission Tomography in Advanced ProstateCancer-Updated Diagnostic Utility, Sensitivity,Specificity, and Distribution of ProstatespecificMembrane Antigen-avid Lesions: ASystematic Review and Meta-analysis. EurUrol. 2020;77(4):403–17. doi: https://doi.org/10.1016/j.eururo.2019.01.049

  14. Motterle G, Ahmed ME, Andrews JR, KarnesRJ. The Role of Radical Prostatectomy andLymph Node Dissection in Clinically NodePositive Patients. Front Oncol. 2019;10(9):1395.doi: https://doi.org/10.3389/fonc.2019.01395

  15. Gandaglia G, Soligo M, Battaglia A, MuilwijkT, Robesti D, Mazzone E, et al. Which Patientswith Clinically Node-positive Prostate CancerShould Be Considered for Radical Prostatectomyas Part of Multimodal Treatment? The Impactof Nodal Burden on Long-term Outcomes.European Urology. 2019;75(5):817–25. doi:https://doi.org/10.1016/j.eururo.2018.10.042

  16. Touijer KA, Karnes RJ, Passoni N, Sjoberg DD,Assel M, Fossati N, et al. Survival Outcomes ofMen with Lymph Node-positive Prostate CancerAfter Radical Prostatectomy: A ComparativeAnalysis of Different Postoperative ManagementStrategies. Eur Urol. 2018;73(6):890–6. doi:https://doi.org/10.1016/j.eururo.2017.09.027

  17. Gupta M, Patel HD, Schwen ZR, TranPT, Partin AW. Adjuvant radiation withandrogen-deprivation therapy for menwith lymph node metastases after radicalprostatectomy: identifying men who benefit.BJU Int. 2019;123(2):252–60. doi: https://doi.org/10.1111/bju.14241

  18. Ventimiglia E, Seisen T, Abdollah F, Briganti A,Fonteyne V, James N, et al. A Systematic Reviewof the Role of Definitive Local Treatmentin Patients with Clinically Lymph NodepositiveProstate Cancer. European UrologyOncology. 2019;2(3):294–301. doi: https://doi.org/10.1016/j.euo.2019.02.001

  19. Seisen T, Vetterlein MW, Karabon P, Jindal T,Sood A, Nocera L, et al. Efficacy of Local Treatmentin Prostate Cancer Patients with Clinically PelvicLymph Node-positive Disease at Initial Diagnosis.Eur Urol. 2018;73(3):452–61. doi: https://doi.org/10.1016/j.eururo.2017.08.011

  20. Zonana F, Sedano L, Ramírez Pérez E.Evaluación y opciones de tratamiento enpacientes con falla posterior a la prostatectomíapor cáncer localizado de la próstata. Rev MexUrol. 2011;71(2):111–27.

  21. Zonana F, Sedano L , Ramírez Pérez E, ZarateOsorno A, García- Sáenz M, Lozano ZalceA. Radioterapia externa en el tratamiento delcáncer de la próstata: experiencia personal1993-2015. Revista Mexicana de Urología.2016 Sep 1;76(5):298-310. doi: https://doi.org/10.48193/revistamexicanadeurologa.v76i5.348

  22. Ali SA, Hoyle A, James ND, Parker C,Brawley G, Attard H., et al. Benefit of prostateradiotherapy only or < 4 bone metastasis andno visceral metastasis, exploratory analyses ofmetastatic site and number in the STAMPEDE“M’/RT comparison. Ann Oncol. 2019;30:V325.

  23. Burdett S, Boevé LM, Ingleby FC, FisherDJ, Rydzewska LH, Vale CL, et al. ProstateRadiotherapy for Metastatic HormonesensitiveProstate Cancer: A STOPCAPSystematic Review and Meta-analysis. EuropeanUrology. 2019;76(1):115–24. doi: https://doi.org/10.1016/j.eururo.2019.02.003.

  24. Siva S, Bressel M, Murphy DG, Shaw M,Chander S, Violet J, et al. Stereotactic AbativeBody Radiotherapy (SABR) for OligometastaticProstate Cancer: A Prospective Clinical Trial.Eur Urol. 2018;74(4):455–62. doi: https://doi.org/10.1016/j.eururo.2018.06.004.

  25. Palma DA, Olson R, Harrow S, Gaede S, LouieAV, Haasbeek C, et al. Stereotactic ablativeradiotherapy versus standard of care palliativetreatment in patients with oligometastaticcancers (SABR-COMET): a randomised,phase 2, open-label trial. The Lancet. 2019May 18;393(10185):2051–8. doi: https://doi.org/10.1016/S0140-6736(18)32487-5.

  26. Patel PH, Chaw CL, Tree AC, Sharabiani M,van As NJ. Stereotactic body radiotherapy forbone oligometastatic disease in prostate cancer.World J Urol. 2019;37(12):2615–21. doi:https://doi.org/10.1007/s00345-019-02873-w.

  27. Gravis G, Fizazi K, Joly F, Oudard S, PriouF, Esterni B, et al. Androgen-deprivationtherapy alone or with docetaxel in non-castratemetastatic prostate cancer (GETUG-AFU 15):a randomised, open-label, phase 3 trial. LancetOncol. 2013;14(2):149–58. doi: https://doi.org/10.1016/S1470-2045(12)70560-0.

  28. Gravis G, Boher J-M, Chen Y-H, Liu G, FizaziK, Carducci MA, et al. Burden of MetastaticCastrate Naive Prostate Cancer Patients, toIdentify Men More Likely to Benefit from EarlyDocetaxel: Further Analyses of CHAARTEDand GETUG-AFU15 Studies. EuropeanUrology. 2018;73(6):847–55. doi: https://doi.org/10.1016/j.eururo.2018.02.001.

  29. Clarke NW, Ali A, Ingleby FC, Hoyle A, AmosCL, Attard G, et al. Addition of docetaxel tohormonal therapy in low- and high-burdenmetastatic hormone sensitive prostate cancer:long-term survival results from the STAMPEDEtrial. Ann Oncol. 2019 Dec 1;30(12):1992–2003.doi: https://doi.org/10.1093/annonc/mdz396.

  30. Fizazi K, Tran N, Fein L, Matsubara N,Rodriguez-Antolin A, Alekseev BY, etal. Abiraterone acetate plus prednisone inpatients with newly diagnosed high-riskmetastatic castration-sensitive prostate cancer(LATITUDE): final overall survival analysisof a randomised, double-blind, phase 3 trial.The Lancet Oncology. 2019;20(5):686–700. doi: https://doi.org/10.1016/S1470-2045(19)30082-8.

  31. Ryan CJ, Smith MR, Fizazi K, Saad F, MuldersPFA, Sternberg CN, et al. Abiraterone acetateplus prednisone versus placebo plus prednisonein chemotherapy-naive men with metastaticcastration-resistant prostate cancer (COUAA-302): final overall survival analysis of arandomised, double-blind, placebo-controlledphase 3 study. Lancet Oncol. 2015;16(2):152–60. doi: https://doi.org/10.1016/S1470-2045(14)71205-7.

  32. Hoyle AP, Ali A, James ND, Cook A, Parker CC,de Bono JS, et al. Abiraterone in ‘High-’ and ‘Lowrisk’Metastatic Hormone-sensitive ProstateCancer. Eur Urol. 2019 Dec;76(6):719–28. doi:https://doi.org/10.1016/j.eururo.2019.08.006

  33. Davis ID, Martin AJ, Stockler MR, Begbie S,Chi KN, Chowdhury S, et al. Enzalutamidewith Standard First-Line Therapy in MetastaticProstate Cancer. N Engl J Med. 2019;381(2):121–31. doi: https://www.nejm.org/doi/10.1056/NEJMoa1903835

  34. Chi KN, Agarwal N, Bjartell A, Chung BH,Pereira de Santana Gomes AJ, Given R, etal. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019Jul 4;381(1):13–24. doi: https://www.nejm.org/doi/10.1056/NEJMoa1903307




2020     |     www.medigraphic.com